Stated plainly: dulaglutide · TRIUMPH-3.
I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious.
My background is quantitative but not chemical, so I can follow an equation more easily than a hand-wave.
Is the standard explanation correct, and if so, what is the evidence for it?
The relevant detail is that two structural interventions do the work: substitution at the DPP-4 cleavage site to stop enzymatic degradation, and a fatty-acid chain to bind serum albumin and create a slowly released reservoir. Remove either and you are back to a compound requiring continuous infusion.
Tirzepatide is an imbalanced dual agonist: it is more potent at the GIP receptor than at the GLP-1 receptor, which is the opposite of what most people assume from the way it is described. Whether the GIP contribution works through central appetite pathways, through adipose insulin sensitisation, or through modulating the GLP-1 signal is genuinely unsettled, and the honest position is that the clinical result is clear and the attribution is not.
The split between delayed gastric emptying and central satiety matters because they have different time courses. Gastric emptying effects show substantial tachyphylaxis over weeks; the central appetite effect does not, or does so much more slowly. That dissociation is the best available explanation for why nausea fades while appetite suppression persists.
Tirzepatide’s imbalanced receptor pharmacology, with greater potency at GIPR than at GLP-1R, is characterised in its pharmacology publication and is the starting point for any mechanistic discussion of the agent[1].
If you want to reason about a new agent, start from its receptor profile and its half-life. Almost everything else follows.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsMechanically, the mechanism question has a clean answer for the peripheral effects and a much less clean answer for the central ones, and it is worth being explicit about which of those you are asking about.
What the glucagon arm of a tri-agonist adds is energy expenditure and hepatic fat mobilisation; what it costs is glycaemic control and an increase in heart rate. That is why the tri-agonists show a steeper weight-loss curve and why their development requires more care around cardiac and glycaemic endpoints than a pure GLP-1 agonist does.
The GIP agonism-versus-antagonism question remains open, and the awkward fact is that both directions have produced weight loss in humans. The reconciling hypothesis is that chronic GIPR agonism produces receptor desensitisation and therefore functions as a pharmacological antagonist, but that is a hypothesis fitted to the data rather than an independent finding.
The mechanism is settled enough to be useful and unsettled enough to be interesting, which is a reasonable place for a field to be.
edited 15 Apr 2025 by RP_C18 — added the citation requested in comments
The relevant detail is that GLP-1R is a class B G-protein-coupled receptor signalling predominantly through Gs and cyclic AMP, and most of the interesting pharmacology in this class is about where that signalling happens rather than how hard it is driven.
Orforglipron is not a peptide at all, which changes everything downstream: it is orally bioavailable without an absorption enhancer, it has no fasting or water requirement of the same kind, it does not require cold chain, and it cannot be assayed by any of the peptide methods discussed elsewhere on this site.
Concretely, receptor desensitisation as a plateau mechanism is plausible and poorly evidenced. GLP-1R internalises on agonist binding and recycles, and biased agonists that internalise less have been argued to sustain signalling better. Whether any of that operates at the timescale of a four-month clinical plateau — against the much simpler explanation that energy expenditure fell with mass — is not established.
I would separate what is established structurally from what is inferred clinically. The chemistry is settled; the attribution of clinical effect to specific receptor arms mostly is not.
Structure predicts pharmacokinetics reliably and clinical effect unreliably. Keep the two claims separate.
Mechanically, start from the receptor and the rest follows: which receptors, in what ratio, with what signalling bias, reached at what concentration.
Comparing a 2.4 mg dose of one agonist to a 15 mg dose of another tells you nothing, because the molar potencies at their respective receptors differ, the receptor profiles differ, and the exposure per milligram differs. The only defensible comparison is between clinical outcomes in trials with comparable populations and durations, which is why SURMOUNT-5 exists and why indirect comparisons should be read sceptically.
The caveat is that mechanism explains and does not predict. A clean mechanistic story has repeatedly failed to survive a Phase 3 in metabolic medicine.
The chemistry is the interesting part and it is also the well-documented part. Read the medicinal chemistry papers; they are short and they explain the design.
On the detail: dose equivalence across agents with different receptor profiles is not a defensible concept, and the attempt to construct it is the most common analytical error in this area.
Oral bioavailability of a 4 kDa peptide is essentially zero without help. Oral semaglutide is co-formulated with sodium N-(8-[2-hydroxybenzoyl]amino)caprylate, which raises local gastric pH and transiently increases transcellular permeability in a small area of gastric mucosa. It works, and it delivers roughly one per cent of the dose, which is why the oral tablet strengths are an order of magnitude above the injectable and why fasting and water volume are not optional details.
Retatrutide’s Phase 2 dose-ranging results reported dose-dependent weight reduction with a tri-agonist across a range of doses, and the magnitude at the top dose is what motivated the Phase 3 TRIUMPH programme[1].
Do not convert doses between agents. There is no exchange rate, and constructing one is how people arrive at an order-of-magnitude error.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.